104 related articles for article (PubMed ID: 3264156)
1. Design and biological activity of a new generation of synthetic C3a analogues by combination of peptidic and non-peptidic elements.
Gerardy-Schahn R; Ambrosius D; Casaretto M; Grötzinger J; Saunders D; Wollmer A; Brandenburg D; Bitter-Suermann D
Biochem J; 1988 Oct; 255(1):209-16. PubMed ID: 3264156
[TBL] [Abstract][Full Text] [Related]
2. Reevaluation of the C3a active site using short synthetic C3a analogues.
Köhl J; Casaretto M; Gier M; Karwath G; Gietz C; Bautsch W; Saunders D; Bitter-Suermann D
Eur J Immunol; 1990 Jul; 20(7):1463-8. PubMed ID: 2387312
[TBL] [Abstract][Full Text] [Related]
3. Functional activities of synthetic anaphylatoxic peptides in widely used biological assays.
Kola A; Klos A; Bautsch W; Kretzschmar T; Köhl J
Clin Exp Immunol; 1992 May; 88(2):368-72. PubMed ID: 1572104
[TBL] [Abstract][Full Text] [Related]
4. Demonstration of a specific C3a receptor on guinea pig platelets.
Fukuoka Y; Hugli TE
J Immunol; 1988 May; 140(10):3496-501. PubMed ID: 3283237
[TBL] [Abstract][Full Text] [Related]
5. Induction of thromboxane release from macrophages by anaphylatoxic peptide C3a of complement and synthetic hexapeptide C3a 72-77.
Hartung HP; Bitter-Suermann D; Hadding U
J Immunol; 1983 Mar; 130(3):1345-9. PubMed ID: 6600482
[TBL] [Abstract][Full Text] [Related]
6. C3a induced activation and stimulus specific reversible desensitization of guinea pig platelets.
Zanker B; Rasokat H; Hadding U; Bitter-Suermann D
Agents Actions Suppl; 1982; 11():147-57. PubMed ID: 6983827
[TBL] [Abstract][Full Text] [Related]
7. Suppression of humoral immune responses by synthetic C3a peptides.
Morgan EL; Weigle WO; Erickson BW; Fok KF; Hugli TE
J Immunol; 1983 Nov; 131(5):2258-61. PubMed ID: 6355293
[TBL] [Abstract][Full Text] [Related]
8. Helical conformation at the carboxy-terminal portion of human C3a is required for full activity.
Hoeprich PD; Hugli TE
Biochemistry; 1986 Apr; 25(8):1945-50. PubMed ID: 3486674
[TBL] [Abstract][Full Text] [Related]
9. Synthetic C3a analogs as specific inhibitors of C3a activity.
Meuer S; Hadding U; Andreatta R; Bitter-Suermann D
Immunopharmacology; 1981 Sep; 3(3):275-80. PubMed ID: 6975766
[TBL] [Abstract][Full Text] [Related]
10. The anaphylatoxic peptide C3a of guinea pig complement. I. Purification, physicochemical and antigenetic properties.
Meuer S; Becker S; Hadding U; Bitter-Suermann D
Z Immunitatsforsch Immunobiol; 1978 Mar; 154(2):135-46. PubMed ID: 77089
[TBL] [Abstract][Full Text] [Related]
11. Synthetic peptides as antagonists of the anaphylatoxin C3a.
Kretzschmar T; Pohl M; Casaretto M; Przewosny M; Bautsch W; Klos A; Saunders D; Köhl J
Eur J Biochem; 1992 Nov; 210(1):185-91. PubMed ID: 1446671
[TBL] [Abstract][Full Text] [Related]
12. Platelet-serotonin release by C3a and C5a: two independent pathways of activation.
Meuer S; Ecker U; Hadding U; Bitter-Suermann D
J Immunol; 1981 Apr; 126(4):1506-9. PubMed ID: 7204973
[TBL] [Abstract][Full Text] [Related]
13. Designing synthetic superagonists of C3a anaphylatoxin.
Ember JA; Johansen NL; Hugli TE
Biochemistry; 1991 Apr; 30(15):3603-12. PubMed ID: 2015217
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning of two isoforms of the guinea pig C3a anaphylatoxin receptor: alternative splicing in the large extracellular loop.
Fukuoka Y; Ember JA; Hugli TE
J Immunol; 1998 Sep; 161(6):2977-84. PubMed ID: 9743361
[TBL] [Abstract][Full Text] [Related]
15. Rational design of antimicrobial C3a analogues with enhanced effects against Staphylococci using an integrated structure and function-based approach.
Pasupuleti M; Walse B; Svensson B; Malmsten M; Schmidtchen A
Biochemistry; 2008 Sep; 47(35):9057-70. PubMed ID: 18690701
[TBL] [Abstract][Full Text] [Related]
16. Cyclic disulfide analogues of the complement component C3a. Synthesis and conformational investigations.
Pohl M; Ambrosius D; Grötzinger J; Kretzschmar T; Saunders D; Wollmer A; Brandenburg D; Bitter-Suermann D; Höcker H
Int J Pept Protein Res; 1993 Apr; 41(4):362-75. PubMed ID: 8496018
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
18. Active sites in complement components C5 and C3 identified by proximity to indels in the C3/4/5 protein family.
Low PJ; Ai R; Ogata RT
J Immunol; 1999 Jun; 162(11):6580-8. PubMed ID: 10352274
[TBL] [Abstract][Full Text] [Related]
19. Contraction of guinea pig lung by synthetic oligopeptides related to human C3a.
Huey R; Erickson BW; Bloor CM; Hugli TE
Immunopharmacology; 1984 Aug; 8(1):37-45. PubMed ID: 6333413
[TBL] [Abstract][Full Text] [Related]
20. Protease-activated receptor-2 (PAR-2): structure-function study of receptor activation by diverse peptides related to tethered-ligand epitopes.
Maryanoff BE; Santulli RJ; McComsey DF; Hoekstra WJ; Hoey K; Smith CE; Addo M; Darrow AL; Andrade-Gordon P
Arch Biochem Biophys; 2001 Feb; 386(2):195-204. PubMed ID: 11368342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
